ClinicalTrials.gg
CompletedNCT02079532Updated Jul 29, 2016Results posted

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor

A Phase 3 interventional study of rituximab [MabThera] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 69 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-07-29.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
16th of 63
302 · median 159
Started
2006
with 10 others
Phase 3
27 of 63
1 open now
Registered
46th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 16th largest by enrollment, is one of 11 that started in 2006, is one of 27 in phase 3, and was the 46th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to one prior anti-TNF alpha inhibitor. MabThera-naive patients will be stratified into 3 arms, according to previous inadequate response to a)etanercept, b)infliximab or c)adalimumab. Patients will be treated with MabThera (1g infusion) on day 1 and day 15, and will continue their basic methotrexate therapy. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, 18-75 years of age;
  • rheumatoid arthritis for >=6 months;
  • previous inadequate response to a single anti-TNF alpha inhibitor;
  • methotrexate at a stable dose range 7.5-25 mg/week.

Exclusion criteria

Exclusion Criteria:

  • other chronic inflammatory articular disease or systemic disease;
  • previous treatment with MabThera or intolerance to MabThera;
  • >=10 mg/day prednisolone within last 2 weeks, or corticosteroids at unstable doses within last 2 weeks;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    MabThera (Rituximab)

    Drug: rituximab [MabThera]

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 24 in Disease Activity Score Based on 28-Joint Count (DAS28)

    The DAS28 consists of swollen joint count (SJC) and tender joint count (TJC) measurements, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and the Patient's Global Assessment of Disease Activity (participant-ated rheumatoid arthritis \[RA\] activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.

    Time frame: Week 24

Secondary outcomes

  1. DAS28 Score

    The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant-rated RA assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.

    Time frame: Screening and Weeks 8, 16, and 24

  2. Percentage of Participants With European League Against Rheumatism (EULAR) Response of Good or Moderate

    The DAS28-based EULAR response criteria were used to measure individual responses as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders experienced a change from baseline of \>1.2 with a DAS28 score ≤3.2 and moderate responders experienced a change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1.

    Time frame: Weeks 8, 16, and 24

  3. Percentage of Participants With Low Disease Activity (DAS28 ≤3.2) at Week 24

    Percentage of participants with low disease activity defined as DAS28 ≤3.2 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).

    Time frame: Week 24

  4. Percentage of Participants Achieving Remission (DAS28 <2.6) at Week 24

    Percentage of participants with remission defined as DAS28 \<2.6 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.

    Time frame: Week 24

  5. Percentage of Participants Achieving a Response By EULAR Category

    Percentage of participants achieving a response by EULAR category, including 'moderate', 'good', or no response at follow-up Weeks 8, 16, and 24. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤ 3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders had a change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with a DAS28 score of \>5.1.

    Time frame: Weeks 8, 16, and 24

  6. Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

    The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific sub-category items. The standard disability score was calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do).

    Time frame: Screening and Weeks 8, 16, and 24

  7. Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score

    The FACIT fatigue scale is base on a 13-item questionnaire to assess the therapy-induced fatigue. Participants were requested to score each question on a scale ranging from 0 (best) to 4 (worst). The scoring system of the FACIT fatigue scale adds up to a total scale ranging from 0 (best) to 52 (worst). The assessment was originally developed for chronic illnesses and is now validated for patients with rheumatoid arthritis (RA). The questionnaire was provided in a German translation.

    Time frame: Screening and Weeks 8, 16, and 24

  8. Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS)

    The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.

    Time frame: Screening and Weeks 8, 16, and 24

  9. SF-36 Domain Scores

    The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to two distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.

    Time frame: Screening and Weeks 8, 16, and 24

  10. Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Response (ACR20/ACR50/ACR70)

    ACR20/50/70 response: ≥20%, ≥50%, or ≥70% improvement, respectively, in tender or swollen joint counts and ≥20%, ≥50%, or ≥70% improvement, respectively, in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Patient's Global Assessment of Disease Activity, 3) Patient's Assessment of Pain, 4) participant assessment of functional disability via a HAQ-DI, and 5) C-reactive protein or ESR at each visit.

    Time frame: Weeks 8, 16, and 24

  11. Swollen Joint Count (SJC)

    The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of swollen joints, each, ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.

    Time frame: Screening and Weeks 8, 16, and 24

  12. Tender Joint Count (TJC)

    The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.

    Time frame: Screening and Weeks 8, 16, and 24

  13. Physician's Global Assessment of Disease Activity

    Physicians assessed the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).

    Time frame: Screening and Weeks 8, 16, and 24

  14. Patient's Assessment of Disease Activity

    Participants were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).

    Time frame: Screening and Weeks 8, 16, and 24

  15. Patient's Assessment of Pain

    Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "unbearable pain".

    Time frame: Screening and Weeks 8, 16, and 24

  16. C-Reactive Protein (CRP)

    Mean CRP as measured as an acute phase reactant by mg per deciliter (mg/dL) at screening, Days 1 and 15, and Weeks 8, 16, and 24.

    Time frame: Screening, Days 1 and 15, and Weeks 8, 16, and 24

  17. Erythrocyte Sedimentation Rate (ESR)

    Mean ESR, as an acute phase reactant, measured in mm/hr at screening, Days 1 and 15, and Weeks 8, 16, and 24.

    Time frame: Screening, Days 1 and 15, and Weeks 8, 16, and 24

  18. Rheumatoid Factor (RF)

    Mean RF as measured by international unit per milliliter (IU/mL) at screening and Weeks 8, 16, and 24.

    Time frame: Screening and Weeks 8, 16, and 24

07

Results

Posted Jun 9, 2015

Participant flow

Participant flow — Overall Study
MilestoneRituximab Plus Methotrexate (MTX)
Started302
Completed273
Not completed29
Withdrew: Adverse event7
Withdrew: Additional or changed therapy2
Withdrew: Lack of efficacy9
Withdrew: Protocol violation3
Withdrew: Withdrawal by subject1
Withdrew: Administrative problems1
Withdrew: Inclusion into refirst3
Withdrew: Other3

Outcome measures

PrimaryChange From Baseline to Week 24 in Disease Activity Score Based on 28-Joint Count (DAS28)

The DAS28 consists of swollen joint count (SJC) and tender joint count (TJC) measurements, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and the Patient's Global Assessment of Disease Activity (participant-ated rheumatoid arthritis \[RA\] activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.

Time frame:
Week 24
Reported as:
Mean · scores on a scale
Change From Baseline to Week 24 in Disease Activity Score Based on 28-Joint Count (DAS28)
scores on a scaleRituximab + MTX
Change From Baseline to Week 24 in Disease Activity Score Based on 28-Joint Count (DAS28)-1.56 ± 1.40
SecondaryDAS28 Score

The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant-rated RA assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.

Time frame:
Screening and Weeks 8, 16, and 24
Reported as:
Mean · scores on a scale
DAS28 Score
scores on a scaleRituximab + MTX
Screening (n=291)5.87 ± 1.05
Week 8 (n=277)4.57 ± 1.30
Week 16 (n=271)4.17 ± 1.31
Week 24 (n=266)4.30 ± 1.47
SecondaryPercentage of Participants With European League Against Rheumatism (EULAR) Response of Good or Moderate

The DAS28-based EULAR response criteria were used to measure individual responses as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders experienced a change from baseline of \>1.2 with a DAS28 score ≤3.2 and moderate responders experienced a change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1.

Time frame:
Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With European League Against Rheumatism (EULAR) Response of Good or Moderate
percentage of participantsRituximab + MTX
Week 8 (n=172)59.1
Week 16 (n=198)68.0
Week 24 (n=188)64.6
SecondaryPercentage of Participants With Low Disease Activity (DAS28 ≤3.2) at Week 24

Percentage of participants with low disease activity defined as DAS28 ≤3.2 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Low Disease Activity (DAS28 ≤3.2) at Week 24
percentage of participantsRituximab + MTX
Percentage of Participants With Low Disease Activity (DAS28 ≤3.2) at Week 2421.6
SecondaryPercentage of Participants Achieving Remission (DAS28 <2.6) at Week 24

Percentage of participants with remission defined as DAS28 \<2.6 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission (DAS28 <2.6) at Week 24
percentage of participantsRituximab + MTX
Percentage of Participants Achieving Remission (DAS28 <2.6) at Week 2411.7
SecondaryPercentage of Participants Achieving a Response By EULAR Category

Percentage of participants achieving a response by EULAR category, including 'moderate', 'good', or no response at follow-up Weeks 8, 16, and 24. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤ 3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders had a change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with a DAS28 score of \>5.1.

Time frame:
Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response By EULAR Category
percentage of participantsRituximab + MTX
Moderate response, Week 845.4
Moderate response, Week 1644.3
Moderate response, Week 2444.0
Good response, Week 813.7
Good response, Week 1623.7
Good response, Week 2420.6
No response, Week 836.1
No response, Week 1625.1
No response, Week 2426.8
SecondaryHealth Assessment Questionnaire - Disability Index (HAQ-DI) Score

The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific sub-category items. The standard disability score was calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do).

Time frame:
Screening and Weeks 8, 16, and 24
Reported as:
Mean · scores on a scale
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
scores on a scaleRituximab + MTX
Screening (n=288)1.60 ± 0.67
Week 8 (n=286)1.43 ± 0.66
Week 16 (n=276)1.33 ± 0.66
Week 24 (n=269)1.32 ± 0.70
SecondaryFunctional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score

The FACIT fatigue scale is base on a 13-item questionnaire to assess the therapy-induced fatigue. Participants were requested to score each question on a scale ranging from 0 (best) to 4 (worst). The scoring system of the FACIT fatigue scale adds up to a total scale ranging from 0 (best) to 52 (worst). The assessment was originally developed for chronic illnesses and is now validated for patients with rheumatoid arthritis (RA). The questionnaire was provided in a German translation.

Time frame:
Screening and Weeks 8, 16, and 24
Reported as:
Mean · scores on a scale
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score
scores on a scaleRituximab + MTX
Screening (n=286)23.81 ± 11.35
Week 8 (n=282)20.87 ± 11.14
Week 16 (n=272)18.92 ± 11.46
Week 24 (n=262)18.53 ± 11.48
SecondaryShort-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS)

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.

Time frame:
Screening and Weeks 8, 16, and 24
Reported as:
Mean · scores on a scale
Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS)
scores on a scaleRituximab + MTX
PCS, Screening (n=287)30.97 ± 8.14
PCS, Week 8 (n=279)34.24 ± 8.56
PCS, Week 16 (n=270)35.92 ± 8.43
PCS, Week 24 (n=264)36.36 ± 9.00
MCS, Screening (n=287)40.88 ± 13.16
MCS, Week 8 (n=279)43.50 ± 12.31
MCS, Week 16 (n=270)45.17 ± 12.32
MCS, Week 24 (n=264)44.92 ± 13.13
SecondarySF-36 Domain Scores

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to two distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.

Time frame:
Screening and Weeks 8, 16, and 24
Reported as:
Mean · scores on a scale
SF-36 Domain Scores
scores on a scaleRituximab + MTX
Physical functioning, Screening (n=289)39.04 ± 24.83
Physical functioning, Week 8 (n=284)43.60 ± 24.50
Physical functioning, Week 16 (n=276)44.64 ± 25.13
Physical functioning, Week 24 (n=268)47.37 ± 26.19
Bodily pain, Screening (n=290)25.94 ± 17.75
Bodily pain, Week 8 (n=285)37.24 ± 19.00
Bodily pain, Week 16 (n=275)44.25 ± 21.60
Bodily pain, Week 24 (n=267)44.06 ± 22.13
Physical role functioning, Screening (n=290)35.11 ± 22.42
Physical role functioning, Week 8 (n=284)43.72 ± 23.95
Physical role functioning, Week 16 (n=276)48.37 ± 23.48
Physical role functioning, Week 24 (n=269)49.63 ± 25.04
Emotional role functioning, Screening (n=289)52.77 ± 31.23
Emotional role functioning, Week 8 (n=282)59.13 ± 27.26
Emotional role functioning, Week 16 (n=276)62.41 ± 27.57
Emotional role functioning, Week 24 (n=268)61.29 ± 27.98
Emotional well-being, Screening (n=289)56.11 ± 20.07
Emotional well-being, Week 8 (n=285)60.43 ± 19.82
Emotional well-being, Week 16 (n=276)63.02 ± 20.51
Emotional well-being, Week 24 (n=268)64.03 ± 21.03
Social functioning, Screening (n=291)56.62 ± 27.23
Social functioning, Week 8 (n=285)64.04 ± 25.87
Social functioning, Week 16 (n=277)65.93 ± 26.10
Social functioning, Week 24 (n=270)66.99 ± 28.11
Vitality, Screening (n=290)38.49 ± 19.41
Vitality, Week 8 (n=285)43.42 ± 19.76
Vitality, Week 16 (n=276)48.25 ± 20.32
Vitality, Week 24 (n=268)48.22 ± 20.75
General health perceptions, Screening (n=291)39.14 ± 14.49
General health perceptions, Week 8 (n=285)45.61 ± 15.06
General health perceptions, Week 16 (n=272)48.54 ± 17.16
General health perceptions, Week 24 (n=269)48.30 ± 17.53
SecondaryPercentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Response (ACR20/ACR50/ACR70)

ACR20/50/70 response: ≥20%, ≥50%, or ≥70% improvement, respectively, in tender or swollen joint counts and ≥20%, ≥50%, or ≥70% improvement, respectively, in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Patient's Global Assessment of Disease Activity, 3) Patient's Assessment of Pain, 4) participant assessment of functional disability via a HAQ-DI, and 5) C-reactive protein or ESR at each visit.

Time frame:
Weeks 8, 16, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Response (ACR20/ACR50/ACR70)
percentage of participantsRituximab + MTX
ACR20, Week 838.8
ACR20, Week 1647.8
ACR20, Week 2446.4
ACR50, Week 813.7
ACR50, Week 1619.9
ACR50, Week 2424.4
ACR70, Week 82.7
ACR70, Week 168.2
ACR70, Week 2410.0
SecondarySwollen Joint Count (SJC)

The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of swollen joints, each, ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.

Time frame:
Screening and Weeks 8, 16, and 24
Reported as:
Mean · swollen joints
Swollen Joint Count (SJC)
swollen jointsRituximab + MTX
Screening (n=291)10.01 ± 5.34
Week 8 (n=288)5.16 ± 4.73
Week 16 (n=282)4.22 ± 4.07
Week 24 (n=272)4.70 ± 4.67
SecondaryTender Joint Count (TJC)

The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.

Time frame:
Screening and Weeks 8, 16, and 24
Reported as:
Mean · tender joints
Tender Joint Count (TJC)
tender jointsRituximab + MTX
Screening (n=291)12.62 ± 6.31
Week 8 (n=288)7.53 ± 6.71
Week 16 (n=282)6.04 ± 6.31
Week 24 (n=272)6.41 ± 6.37
SecondaryPhysician's Global Assessment of Disease Activity

Physicians assessed the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).

Time frame:
Screening and Weeks 8, 16, and 24
Reported as:
Mean · mm
Physician's Global Assessment of Disease Activity
mmRituximab + MTX
Screening (n=291)63.99 ± 15.40
Week 8 (n=286)39.20 ± 19.85
Week 16 (n=280)33.03 ± 19.96
Week 24 (n=271)35.75 ± 23.92
SecondaryPatient's Assessment of Disease Activity

Participants were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).

Time frame:
Screening and Weeks 8, 16, and 24
Reported as:
Mean · mm
Patient's Assessment of Disease Activity
mmRituximab + MTX
Screening (n=291)63.49 ± 20.88
Week 8 (n=286)46.19 ± 23.51
Week 16 (n=278)41.25 ± 24.99
Week 24 (n=270)41.47 ± 25.50
SecondaryPatient's Assessment of Pain

Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "unbearable pain".

Time frame:
Screening and Weeks 8, 16, and 24
Reported as:
Mean · mm
Patient's Assessment of Pain
mmRituximab + MTX
Screening (n=291)62.78 ± 20.80
Week 8 (n=287)47.30 ± 23.26
Week 16 (n=276)42.11 ± 25.14
Week 24 (n=269)41.76 ± 25.52
SecondaryC-Reactive Protein (CRP)

Mean CRP as measured as an acute phase reactant by mg per deciliter (mg/dL) at screening, Days 1 and 15, and Weeks 8, 16, and 24.

Time frame:
Screening, Days 1 and 15, and Weeks 8, 16, and 24
Reported as:
Mean · mg/dL
C-Reactive Protein (CRP)
mg/dLRituximab + MTX
Screening (n=289)1.82 ± 2.35
Day 1 (n=233)1.60 ± 1.96
Day 15 (n=286)1.81 ± 2.27
Week 8 (n=283)1.31 ± 1.44
Week 16 (n=281)1.21 ± 1.65
Week 24 (n=269)1.30 ± 1.77
SecondaryErythrocyte Sedimentation Rate (ESR)

Mean ESR, as an acute phase reactant, measured in mm/hr at screening, Days 1 and 15, and Weeks 8, 16, and 24.

Time frame:
Screening, Days 1 and 15, and Weeks 8, 16, and 24
Reported as:
Mean · mm/hr
Erythrocyte Sedimentation Rate (ESR)
mm/hrRituximab + MTX
Screening (n=291)30.20 ± 20.56
Day 1 (n=225)28.07 ± 19.51
Day 15 (n=277)30.61 ± 21.46
Week 8 (n=279)24.85 ± 16.68
Week 16 (n=276)22.28 ± 16.58
Week 24 (n=268)23.64 ± 17.36
SecondaryRheumatoid Factor (RF)

Mean RF as measured by international unit per milliliter (IU/mL) at screening and Weeks 8, 16, and 24.

Time frame:
Screening and Weeks 8, 16, and 24
Reported as:
Mean · IU/mL
Rheumatoid Factor (RF)
IU/mLRituximab + MTX
Screening (n=279)178.23 ± 352.61
Week 8 (n=255)109.84 ± 213.32
Week 16 (n=259)88.22 ± 174.99
Week 24 (n=258)87.52 ± 187.94

Adverse events

Collected over From first dose of study drug up to 24 weeks of follow up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab + MTX—36/302 (11.9%)62/302 (20.5%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventRituximab + MTX
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders9/302
Infections and infestationsInfections and infestations7/302
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications7/302
Gastrointestinal disordersGastrointestinal disorders5/302
Cardiac disordersCardiac disorders3/302
General disorders and administration site conditionsGeneral disorders2/302
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps)2/302
Nervous system disordersNervous system disorders2/302
Ear and labyrinth disordersEar and labyrinth disorders1/302
Endocrine disordersEndocrine disorders1/302
Most frequent other events
Most frequent other events
EventRituximab + MTX
NasopharyngitisInfections and infestations37/302
CoughRespiratory, thoracic and mediastinal disorders19/302
HypertensionVascular disorders17/302

Baseline characteristics

Safety population: all participants who received at least 1 dose of trial medication and had at least 1 safety follow-up.

Age, Continuous
Age, Continuous(years)Rituximab + MTX
Mean54.4 ± 18.77
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + MTX
Female228
Male74
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Rituximab + MTX
Caucasian301
Asian1
08

Study locations

69 sites
  • Bad Abbach, 93077, Germany
  • Bad Aibling, 83043, Germany
  • Bad Bramstedt, 24576, Germany
  • Bamberg, 96047, Germany
  • Berlin, 10117, Germany
  • Berlin, 12200, Germany
  • Berlin, 13055, Germany
  • Berlin, 13125, Germany
  • Berlin, 13589, Germany
  • Berlin, 14163, Germany
  • Bonn, 53111, Germany
  • Bremen, 28199, Germany
  • Cuxhaven, 27476, Germany
  • Damp, 24351, Germany
  • Donaueschingen, 78166, Germany
  • Dresden, 01109, Germany
  • Düsseldorf, 40211, Germany
  • Düsseldorf, 40225, Germany
  • Erfurt, 99096, Germany
  • Erlangen, 91054, Germany
  • Erlangen, 91056, Germany
  • Essen, 45239, Germany
  • Essen, 45326, Germany
  • Frankfurt Am Main, 60590, Germany
  • Freiburg, 79106, Germany
  • Fulda, 36039, Germany
  • GIEßEN, 35392, Germany
  • Gommern, 39245, Germany
  • Göttingen, 37075, Germany
  • Hagen, 58135, Germany
  • Halle, 06120, Germany
  • Hamburg, 22081, Germany
  • Hannover, 30159, Germany
  • Hannover, 30625, Germany
  • Heidelberg, 69120, Germany
  • Herne, 44652, Germany
  • Hofheim, 65719, Germany
  • Homburg/saar, 66424, Germany
  • Jena, 07743, Germany
  • Karlsruhe, 76135, Germany
  • Köln, 50924, Germany
  • Ludwigshafen, 67063, Germany
  • Mainz, 55122, Germany
  • Mainz, 55131, Germany
  • Mittelherwigsdorf, 02763, Germany
  • Muenchen, 80336, Germany
  • Mönchengladbach, 41061, Germany
  • München, 80335, Germany
  • München, 81541, Germany
  • Münster, 48149, Germany
  • Naunhof, 04683, Germany
  • Oldenburg, 26121, Germany
  • Osnabrück, 49074, Germany
  • Pirna, 01796, Germany
  • Ratingen, 40882, Germany
  • Rostock, 18059, Germany
  • Schwerte, 58239, Germany
  • Sendenhorst, 48324, Germany
  • Stuttgart, 70178, Germany
  • Treuenbrietzen, 14929, Germany
  • Trier, 54292, Germany
  • Tübingen, 72076, Germany
  • ULM, 89081, Germany
  • Wiesbaden, 65189, Germany
  • Wiesbaden, 65191, Germany
  • Wuerzburg, 97080, Germany
  • Wuppertal, 42105, Germany
  • Würselen, 52146, Germany
  • Zeven, 27404, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2014
First posted
Mar 5, 2014
Start
Nov 2006
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Jun 9, 2015
Last update
Jul 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02079532
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 5, 2014
Start date
Nov 2006
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Jun 9, 2015
Last update
Jul 29, 2016

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion